Fuda Cancer Hospital is considered one of the BEST cancer hospitals in China by patients and is affiliated to Jinan University and Translational Medicine Center of Guangzhou Institute of Biomedicine and Health of Chinese Academy of Sciences. As a tertiary hospital, Fuda operates with international standards and was selected as the National Key Clinical Specialty (Oncology) in 2010. In 2014, Fuda was accredited by the Joint Commission International (JCI), a golden standard of medical service worldwide.Fuda is equipped with 400 beds, 45 VIP rooms and 500 medical staffs to help our patients. Multiple Disciplinary Teams work in Fuda to personalize treatment for every single patient. Those teams include NanoKnife Ablation team (irreversible electroporation), Cryosurgical ablation team, cancer micro-vascular intervention team, combined immunotherapy team, and surgical team. Our clinical achievement and academic research are widely accepted by peer doctors and scientific journals. In Fuda, Doctors use more than 20 types of cancer treatment, including those mentioned above, to help our patient LIVE WITH CANCER as long as possible with a quality life. Fuda highly focuses on research and application of advanced clinical procedures and pays tremendous attention on patient care. In the past two decades, Fuda has been active in promoting Minimally Invasive Treatments such as Cryosurgery, NanoKnife, micro-vascular intervention treatment and Brachytherapy. Fuda was the first in China to introduce NanoKnife for clinical use and has accumulated substantial clinical experience. Patients are not just receiving treatment in Fuda, they live a life in Fuda with their family. To date, patients from over 110 countries were treated in Fuda and 50% of them are from South-East Asia, the Middle East, Oceania, Europe and North America. The number of patients treated in Fuda with Minimally Invasive treatments outnumbers any other hospital in the world. Fuda has received various awards in China and abroad for outstanding achievements in treating cancers and has been highly praised by patients worldwide.